方法：选取2011-01/2016-01我院确诊DR患者120例240眼进行回顾性分析，根据是否采用羟苯磺酸钙治疗分为：联合组60例120眼采用PRP联合羟苯磺酸钙治疗，对照组60例120眼仅采取PRP治疗，对比两组患者的最佳矫正视力(best corrected visual acuity，BCVA)、黄斑中心凹厚度(central fovea of macula thickness，CMT)及临床疗效。

结果：治疗前，联合组和对照组的BCVA差异无统计学意义(P>0.05)； 治疗后，联合组的BCVA值好于对照组，差异有统计学意义(P<0.01)； 治疗前，联合组和对照组的CMT、新生血管荧光素渗漏面积差异无统计学意义(P>0.01)； 治疗后，联合组的CMT、新生血管荧光素渗漏面积值小于对照组，差异有统计学意义(P<0.01)； 治疗后，联合组显效65.0%、有效30.0%、无效5.0%，对照组显效50.8%、有效36.7%、无效12.5%，两组比较差异具有统计学意义(P<0.05)。

结论：PRP联合羟苯磺酸钙治疗PDR较单纯PRP具有更显著的临床效果。

METHODS: Selected 120 cases(240 eyes)of DR diagnosed in our hospital from January 2011 to January 2016 were retrospectively analyzed. According to whether calcium dobesilate was used, the treatment group was divided into two groups. Sixty cases were treated with PRP combined with calcium dobesilate, and 60 cases in the control group were treated with PRP only. The BCVA, CMT and clinical efficacy of the two groups were compared.

RESULTS: Before treatment, there was no significant difference on BCVA between combined group and control group(P>0.05). After treatment, BCVA of combined group was higher than that of the control group(P<0.01). Before the treatment, no statistically significant difference between combined group and control group on CMT, neovascularization and fluorescein leakage area were found(P>0.05); after treatment, the combination group on CMT, neovascularization and fluorescein leakage area value were less than the control group(P<0.01). After treatment, combined group was appearance effect in 65.0%, effective in 30.0%, invalid in 5.0%, the control group was 50.8%, effective 36.7%, invalid 12.5%, all statistically significant differences between the two groups(P<0.05).

CONCLUSION:PRP combined with calcium dobesilate in treatment of DR has a more significant clinical effect than PRP alone.